Please enable Javascript
ASCO GU 2023-Prostate Cancer
Novel Approaches for Risk Stratifying Newly Diagnosed Localized Prostate Cancer
Phouc T. Tran, MD, PhD
ASCO GU Symposium 2023
|
February 24, 2023
Phouc Tran, MD, PhD, highlights the challenges of accurate risk stratification for newly diagnosed localized prostate cancer.
View More
TRITON3: Interim OS, Efficacy of Rucaparib Versus Chemo for mCRPC
Alan H. Bryce, MD
ASCO GU Symposium 2023
|
February 24, 2023
Alan H. Bryce, MD, highlights the positive TRITON3 data for rucaparib as a new standard of care for patients with mCRPC.
View More
Treating Metastatic Prostate Cancer: Rucaparib or Physician’s Choice?
Emily Menendez
ASCO GU Symposium 2023
|
February 17, 2023
At the 2023 ASCO GU Symposium, Alan Bryce, MD, presented results from the TRITON3 study on rucaparib vs physician’s choice.
Read More
PROpel: Final OS of First-Line Abiraterone Plus Olaparib for mCRPC
Noel Clarke, MBBS, FRCS, ChM
ASCO GU Symposium 2023
|
February 24, 2023
Noel Clarke, MBBS, FRCS, ChM, explains the PROpel study design and what the overall survival data shows at data cutoff 3.
View More
Novel Guidelines for PSMA PET Staging of Localized Prostate Cancer
David Nanus, MD
ASCO GU Symposium 2023
|
February 24, 2023
David Nanus, MD, details the ways in which PSMA PET varies in guidelines and is used to stage localized prostate cancer.
View More
TALAPRO-2: Phase 3 Results of Talazoparib Plus Enzalutamide for mCRPC
Neeraj Agarwal, MD
ASCO GU Symposium 2023
|
February 24, 2023
Neeraj Agarwal, MD, highlights the significance of TALAPRO-2 in mCRPC and the data for rPFS with respect to HRR status.
View More
Evaluation of ctDNA in Patients With CRPC, Pathogenic Germline Mutations in BRCA2
Zachary Bessette
ASCO GU Symposium 2023
|
February 16, 2023
A new study examined the relationship between pathogenic germline BRCA2 mutation and somatic change in circulating tumor DNA.
Read More
Radical Prostatectomy Outcomes for Locally Advanced, Node-Positive, and Metastatic Prostate Cancer
Zachary Bessette
ASCO GU Symposium 2023
|
February 16, 2023
Radical prostatectomy for patients with locally advanced, node-positive, and metastatic PC may be an effective option.
Read More
Patterns of Failure Detected by PSMA PET After Primary, Salvage Radiotherapy for Prostate Cancer
Zachary Bessette
ASCO GU Symposium 2023
|
February 16, 2023
A cohort analysis found that PSMA PET at baseline, before pRT, or before sRT may predict from pelvic radiotherapy.
Read More
Novel Radiomic-Based Diagnostic Tool Identifies Patients at High Risk for Prostate Cancer Recurrence
Zachary Bessette
ASCO GU Symposium 2023
|
February 16, 2023
A new analysis demonstrates “excellent potential” for a radiomic-based diagnostic tool to identify PC recurrence risk.
Read More
Assessing Utilization Patterns of mHSPC Treatment in a Community Oncology Practice Setting
Zachary Bessette
ASCO GU Symposium 2023
|
October 12, 2023
An analysis highlighted real-world treatment of patients with mHSPC in the community who received at least 1 line of therapy.
Read More
Transrectal Ultrasound Versus MRI for Estimating Prostatic Volume
Zachary Bessette
ASCO GU Symposium 2023
|
February 16, 2023
A comparative effectiveness study showed the optimal method of determining prostatic volume of prostate cancer.
Read More
Race Impacts Survival, Use of Health Care Resources for Medicaid-Insured Adults With mCSPC
Emily Menendez
ASCO GU Symposium 2023
|
August 23, 2023
A study assessed the differences in OS and health care resource utilization by race in Medicaid-insured patients with mCSPC.
Read More
Developing a Biopsy-Based 6-Gene Signature to Risk-Stratify Patients With Early-Stage Prostate Cancer
Emily Menendez
ASCO GU Symposium 2023
|
February 16, 2023
Researchers used 14 prognostic genes to make a biopsy-based 6-gene signature to risk-stratify patients with early-stage PCa.
Read More
Neuroendocrine Differentiation Impacts Efficacy of First-Line Abiraterone or Docetaxel for mCRPC
Emily Menendez
ASCO GU Symposium 2023
|
February 16, 2023
A study reviewed the prognostic value of neuroendocrine differentiation in mCRPC patients receiving abiraterone or docetaxel.
Read More
Prostate Cancer Takes Center Stage at the ASCO GU Symposium 2023
Zachary Bessette
ASCO GU Symposium 2023
|
February 8, 2023
Gerhardt Attard, MD, PhD, FRCP, will kick off the event with a session on advanced prostate cancer.
Read More
Advertisement
Advertisement